Skip to main content
. 2021 Feb 19;16(2):e0247017. doi: 10.1371/journal.pone.0247017

Fig 1. Characterization of ADAMTS13 activity, ADAMTS13 antigen, and VWF antigen in ICU patient samples.

Fig 1

(A) ADAMTS13 activity in septic patients, non-septic patients, and healthy controls (day 1). (B) ADAMTS13 activity in non-survivors septic (NS), survivor septic (S), non-septic, and healthy controls at day 1 and day last. (C) ADAMTS13 antigen in septic patients, non-septic patients, and healthy controls (day 1). (D) ADAMTS13 antigen in non-survivors septic, survivor septic, non-septic, and healthy controls at day 1 and day last. (E) VWF antigen levels in septic patients, non-septic patients, and healthy controls (day 1). (F) VWF antigen in non-survivor septic, survivor septic, non-septic, and healthy controls at day 1 and day last. All ADAMTS13 activity, ADAMTS13 antigen, and VWF antigen values normalized to pooled healthy control plasma and expressed as percentage (mean±SD). Dunnett’s multiple comparisons test (one-way ANOVA). Paired t-test performed to assess change between day 1 and day last. ****p≤0.0001, ***p≤0.001, **p≤0.01, *p≤0.05, and N.S. p>0.05.